Rapid amelioration of hyperglycemia facilitated by dasatinib in a chronic myeloid leukemia patient with type 2 diabetes mellitus.

@article{Ono2012RapidAO,
  title={Rapid amelioration of hyperglycemia facilitated by dasatinib in a chronic myeloid leukemia patient with type 2 diabetes mellitus.},
  author={Keiko Ono and Hitoshi Suzushima and Yuko Watanabe and Yoshitaka Kikukawa and Taizou Shimomura and Noboru Furukawa and Tatsuya Kawaguchi and Eiichi Araki},
  journal={Internal medicine},
  year={2012},
  volume={51 19},
  pages={2763-6}
}
Tyrosine kinase inhibitors (TKIs) have been shown to affect glucose metabolism in patients with chronic myeloid leukemia (CML); however, their precise mechanism of action remains unknown. We herein report the case of a 57-year-old diabetic CML patient who was resistant to imatinib and initially required 20 units of insulin daily to control his blood glucose levels. After the initiation of dasatinib, the patient's insulin requirements declined rapidly and insulin treatment was discontinued… CONTINUE READING